Vasogen Announces New Class Of Pharmaceuticals Targeting Chronic Inflammation

[Andrew]

Vasogen claims that it has identified a new class of pharmaceuticals, based on proprietary synthetic lipid technology, targeting chronic inflammation. The company's first drug candidate in this class, VP025, is being developed for the treatment of neuroinflammatory conditions, such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (Lou Gehrig's disease). Preclinical findings demonstrate the ability of VP025 to significantly reduce key measures of inflammation and cell death in the brain and improve physiological measurements that correlate with memory and learning activity.